Publications


Results 1-161 of 161 (Search time: 0.008 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12022Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapyTA-CHEN HUANG ; Liang C.-W.; Li Y.-I.; GUO, JHE-CYUAN ; CHIA-CHI LIN ; Chen Y.-J.; ANN-LII CHENG ; CHIH-HUNG HSU Journal of Cancer Research and Clinical Oncology22
22022Immunotherapy in anaplastic thyroid cancer: Case seriesSHYANG-RONG SHIH ; Chen, Kuan-Hua; Lin, Kuan-Yu; PAN-CHYR YANG ; KUEN-YUAN CHEN ; CHUN-WEI WANG ; Chun-Nan Chen ; CHIH-FENG LIN ; CHIA-CHI LIN Journal of the Formosan Medical Association = Taiwan yi zhi55
32022Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter studyZucali P.A.; CHIA-CHI LIN ; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN ; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J.Journal for ImmunoTherapy of Cancer1915
42022A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesShimizu T.; Kuboki Y.; CHIA-CHI LIN ; Yonemori K.; Yanai T.; Faller D.V.; Dobler L.; Gupta N.; Sedarati F.; Kim K.-P.Targeted Oncology45
52022First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaItaliano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V.Cancer Immunology, Immunotherapy45
62021Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor SitesGUO, JHE-CYUAN ; Lin, Chen Yuan; CHIA-CHI LIN ; TA-CHEN HUANG ; Lien, Ming Yu; LI-CHUN LU ; HUNG-YANG KUO ; CHIH-HUNG HSU ONCOLOGY (United States)11
72021Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasmChang, Ling-Kai; Chen, Kuan-Chih; MEI-FANG CHENG ; CHIA-CHI LIN ; HSIU-PO WANG ; Sung, Chia-Tung; Chen, Jou-Ho; RUOH-FANG YEN ; CHIA-LIN HSU ; SHYANG-RONG SHIH Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society22
82021Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' OrbitopathySHYANG-RONG SHIH ; SHU-LANG LIAO ; Shih, Chih-Wei; YI-HSUAN WEI ; Lu, Ting-Xuan; Chou, Chien-Hsiang; Yen, Er-Yen; YI-CHENG CHANG ; CHIA-CHI LIN ; Chi, Yu-Chiao; WEI-SHIUNG YANG ; FENG-CHIAO TSAI Ocular immunology and inflammation44
92021Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLCBIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG JTO clinical and research reports10
102021Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsPark K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN JTO Clinical and Research Reports40
112021Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitorsCHIA-CHI LIN Journal of Immunotherapy and Precision Oncology200
122021Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 ConsortiumShimizu T.; Kim D.-W.; Loong H.H.; CHIA-CHI LIN ; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W.Asia-Pacific Journal of Clinical Oncology21
132021Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialBrose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; CHIA-CHI LIN ; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J.The Lancet Oncology10998
142021Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studySubbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; CHIA-CHI LIN ; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H.The Lancet Diabetes and Endocrinology164140
152021Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab DeruxtecanYin O.; Iwata H.; CHIA-CHI LIN ; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F.Clinical Pharmacology and Therapeutics1615
162021Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsHollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; CHIA-CHI LIN ; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J.Clinical Cancer Research2421
172021Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trialPatnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; CHIA-CHI LIN ; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J.Clinical Cancer Research1817
182021Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumorsCurigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; CHIA-CHI LIN ; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A.Clinical Cancer Research117108
192021Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsLewis J.H.; Gelderblom H.; van de Sande M.; Stacchiotti S.; Healey J.H.; Tap W.D.; Wagner A.J.; Pousa A.L.; Druta M.; CHIA-CHI LIN ; Baba H.A.; Choi Y.; Wang Q.; Shuster D.E.; Bauer S.Oncologist2121
202021Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumorsTakahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; CHIA-CHI LIN ; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J.Clinical Cancer Research1210
212021Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid TumorsShiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T.Oncologist10
222021Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in AsiaCHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S.Targeted Oncology1512
232020Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsCHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU European Journal of Cancer5246
242020Rational combination with an immunotherapy backbone in genitourinary cancersJHE-CYUAN GUO ; CHIA-CHI LIN Urological Science33
252020An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerBible K.C.; Menefee M.E.; CHIA-CHI LIN ; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C.Thyroid1513
262020Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; CHIA-CHI LIN European Journal of Cancer8176
272020Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsDrilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C.The Lancet Oncology286241
282020Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLCTan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F.Journal of Thoracic Oncology2927
292020Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib StudyCHIA-CHI LIN ; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU Oncologist43
302020Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibCHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU Oncologist1515
312020PD-1 blockade in anaplastic thyroid carcinomaCapdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; CHIA-CHI LIN ; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M.Journal of Clinical Oncology147122
322020Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsDesai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M.Journal for ImmunoTherapy of Cancer7267
332020Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaSi L.; Zhang X.; Shin S.J.; Fan Y.; CHIA-CHI LIN ; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J.European Journal of Cancer117
342020A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsJIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN Investigational New Drugs3734
352020An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLCZhu, Viola W; YEN-TING LIN ; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; CHIA-CHI LIN ; Soo, Ross AJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer4236
362020Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsBang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B.Cancer Science4035
372020A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignanciesYamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T.Investigational New Drugs1514
382020Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumorsStrickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K.Molecular Cancer Therapeutics1514
392020A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsNaing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M.Journal for ImmunoTherapy of Cancer5146
402020Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialPetrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; van der Heijden M.S.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Matsubara N.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; CHIA-CHI LIN ; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Alekseev B.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Necchi A.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.The Lancet Oncology5648
412020Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerPeters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.Lung Cancer1312
422020Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE TrialDrakaki A.; Kirby C.J.; Van Der Heijden M.S.; Petrylak D.P.; Powles T.; Chi K.N.; Fl?chon A.; Necchi A.; G?czi L.; Lee J.-L.; Gakis G.; Bracarda S.; Chowdhury S.; CHIA-CHI LIN ; Keizman D.; Vaishampayan U.N.; Zimmermann A.H.; Bell-Mcguinn K.; Castellano D.Bladder Cancer22
432020Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 TrialPaz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C.Journal of Thoracic Oncology10690
442020Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursde Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG British Journal of Cancer1917
452019Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder CancerCHIANG, YUN ; Wang, Chung-Chieh; YU-CHIEH TSAI ; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG Journal of clinical medicine76
462019Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsJHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU Anticancer research2828
472019Should we design clinical trials differently in the era of cancer immunotherapy?CHIA-CHI LIN Journal of Immunotherapy and Precision Oncology30
482019An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaEl Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K.Oncologist6659
492019Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsDoi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN Targeted Oncology2014
502019A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasCHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J.British Journal of Cancer1511
512019Challenges of the phase I drug development in non-small cell lung cancerCHIA-CHI LIN Chinese Clinical Oncology78
522019Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatmentSHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YIH-LEONG CHANG ; MIN-SHU HSIEH ; CHIA-HSIEN CHENG European Journal of Surgical Oncology96
532019Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective StudyWEI-LI MA ; CHIA-CHI LIN ; FENG-MING HSU ; JANG-MING LEE ; JIN-SHING CHEN ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Chao Y.-T.; Chang C.-H.; CHIH-HSIN YANG Clinical Lung Cancer99
542019Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerMehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B.BMC Cancer122108
552019Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trialShaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; CHIA-CHI LIN ; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.The Lancet Oncology208170
562019ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancerShaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F.Journal of Clinical Oncology257208
572019Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinomaTa-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU Journal of the Formosan Medical Association86
582019Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patientsZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU European Journal of Cancer2722
592018A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinomaSHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH Anticancer Research32
602018Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012Tahara M.; Muro K.; Hasegawa Y.; Chung H.C.; CHIA-CHI LIN ; Keam B.; Takahashi K.; Cheng J.D.; Bang Y.-J.Cancer Science4141
612018Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in TaiwanSHU-YUNG LIN ; Yang C.-Y.; BIN-CHI LIAO ; CHAO-CHI HO ; WEI-YU LIAO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Hsu W.-H.; KANG-YI SU ; YIH-LEONG CHANG ; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU Journal of Cancer4041
622018TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: Results from an open-label, non-randomized phase 1 studyBang Y.-J.; Takano T.; CHIA-CHI LIN ; Fasanmade A.; Yang H.; Danaee H.; Asato T.; Kalebic T.; Wang H.; Doi T.Cancer Research and Treatment66
632018Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studySolomon B.J.; Besse B.; Bauer T.M.; Felip E.; Soo R.A.; Camidge D.R.; Chiari R.; Bearz A.; CHIA-CHI LIN ; Gadgeel S.M.; Riely G.J.; Tan E.H.; Seto T.; James L.P.; Clancy J.S.; Abbattista A.; Martini J.-F.; Chen J.; Peltz G.; Thurm H.; Ignatius Ou S.-H.; Shaw A.T.The Lancet Oncology552453
642018Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyCHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG The Lancet Respiratory Medicine115109
652018Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer PatientsWu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG Clinical Lung Cancer1617
662018Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG Journal of the Formosan Medical Association119
672018Response to Nivolumab as Salvage Therapy in a Patient with Thymic CarcinomaYang P.-C.; JHE-CYUAN GUO ; MIN-SHU HSIEH ; CHIA-CHI LIN ; CHIH-HUNG HSU Journal of Thoracic Oncology53
682018Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapyJHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE Anticancer Research1211
692018Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancersJIN-YING LU ; WERN-CHERNG CHENG ; KUEN-YUAN CHEN ; CHIA-CHI LIN ; CHING-CHUNG CHANG ; KUAN-TING KUO ; PEI-LUNG CHEN Journal of the Formosan Medical Association31
702018Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?PEI-MING HUANG ; Feng-Ming Hsu ; CHIA-CHI LIN ; Hsu C.-H.; CHIA-HSIEN CHENG ; JANG-MING LEE Digestive Surgery44
712018Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012Mehra R.; Seiwert T.Y.; Gupta S.; Weiss J.; Gluck I.; Eder J.P.; Burtness B.; Tahara M.; Keam B.; Kang H.; Muro K.; Geva R.; Chung H.C.; CHIA-CHI LIN ; Aurora-Garg D.; Ray A.; Pathiraja K.; Cheng J.; Chow L.Q.M.; Haddad R.British Journal of Cancer278256
722018Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Opinion on Pharmacotherapy55
732017A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvementYUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU Journal of the Formosan Medical Association76
742017Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapyBIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG Lung Cancer3835
752017Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinibZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU Oncologist2425
762017Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialPetrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee Y.-G.; Cort?s L.V.; Flores C.L.U.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; van der Heijden M.S.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Pulido E.G.; Mignorance J.I.D.; Gauna D.C.; Rodr?guez-Vida A.; Su Y.-L.; Lin C.-L.; Matsubara N.; CHIA-CHI LIN ; Yeh S.-P.; ?i?in I.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.; Syndikus I.; Alekseev B.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.; Pan C.X.; Schwarz J.; Cultrera J.; Hainsworth J.; Herms B.; Necchi A.; Lawler W.; Lowe T.; Tagawa S.; Aragon-Ching J.; Vaishampayan U.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Hegemann M.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; del Muro X.G.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Widau R.C.; Liepa A.M.; Walgren R.A.; Hamid O.; Zimmermann A.H.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Ng S.S.W.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Flechon A.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Gakis G.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Geczi L.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.The Lancet135122
772017New data on clinical decisions in NSCLC patients with uncommon EGFR mutationsWu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG Expert Review of Respiratory Medicine1514
782017Timing of multikinase inhibitor initiation in differentiated thyroid cancerBrose M.S.; Smit J.; CHIA-CHI LIN ; Pitoia F.; Fellous M.; De Sanctis Y.; Schlumberger M.; Tori M.; Sugitani I.Endocrine-Related Cancer2927
792017A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerReynolds K.L.; Bedard P.L.; Lee S.-H.; Chia-Chi Lin ; Tabernero J.; Alsina M.; Cohen E.; Baselga J.; Blumenschein G.; Graham D.M.; Garrido-Laguna I.; Juric D.; Sharma S.; Salgia R.; Seroutou A.; Tian X.; Fernandez R.; Morozov A.; Sheng Q.; Ramkumar T.; Zubel A.; Bang Y.-J.BMC Cancer2120
802017Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension componentCHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A.Journal of Clinical Oncology441443
812017Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of AfatinibBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Current Oncology Reports1819
822017Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyAhn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG The Lancet Respiratory Medicine8067
832017Optimal usage of radium-223 in metastatic castration-resistant prostate cancerCha T.-L.; Wu T.T.-L.; Vogelzang N.J.; CHAO-YUAN HUANG ; Huang S.-P.; CHIA-CHI LIN ; Ou Y.-C.; Pang S.-T.; Shen D.H.-Y.; Wu W.-J.; Chang W.Y.-H.Journal of the Formosan Medical Association1412
842016Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancerChen, Kai-Lung; CHIA-CHI LIN ; YUNG-TSU CHO ; Yang, Che-Wen; YI-SHUAN SHEEN ; Tsai, Hsiao-En; CHIA-YU CHU JAMA Dermatology2620
852016Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 studyCHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K.Journal of Thoracic Oncology2220
862016Obesity and outcomes in patients with metastatic urothelial carcinomaLeiter A.; Doucette J.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Bamias A.; Oh W.K.; Galsky M.D.Bladder Cancer60
872016Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohortChow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y.Journal of Clinical Oncology644141
882016Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsBIN-CHI LIAO ; CHIA-CHI LIN ; JIH-HSIANG LEE ; CHIH-HSIN YANG Journal of Biomedical Science4237
892016Safety of gefitinib in non-small cell lung cancer treatmentHsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Opinion on Drug Safety1715
902016151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIsBIN-CHI LIAO ; Bai Y.-Y.; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG Journal of Thoracic Oncology11
912016Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)Motzer R.J.; Alyasova A.; Ye D.; Karpenko A.; Li H.; Alekseev B.; Xie L.; Kurteva G.; Kowalyszyn R.; Karyakin O.; Neron Y.; Cosgriff T.; Collins L.; Brechenmacher T.; CHIA-CHI LIN ; Morgan L.; Yang L.Annals of Oncology3534
922016Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumorsMinami H.; Ando Y.; Ma B.B.Y.; Hsiang Lee J.; Momota H.; Fujiwara Y.; Li L.; Fukino K.; Ito K.; Tajima T.; Mori A.; CHIA-CHI LIN Cancer Science1715
932016Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancerHsiue E.H.-C; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG Expert Review of Molecular Diagnostics1514
942016Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialMuro K.; Chung H.C.; Shankaran V.; Geva R.; Catenacci D.; Gupta S.; Eder J.P.; Golan T.; Le D.T.; Burtness B.; McRee A.J.; CHIA-CHI LIN ; Pathiraja K.; Lunceford J.; Emancipator K.; Juco J.; Koshiji M.; Bang Y.-J.The Lancet Oncology856787
952016Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1)De Santis M.; Wiechno P.J.; Bellmunt J.; Lucas C.; Su W.-C.; Albiges L.; CHIA-CHI LIN ; Senkus-Konefka E.; Flechon A.; Mourey L.; Necchi A.; Loidl W.C.; Retz M.M.; Vaissi?re N.; Culine S.Annals of Oncology4639
962015RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaRavaud A.; Barrios C.H.; Alekseev B.; Tay M.-H.; Agarwala S.S.; Yalcin S.; CHIA-CHI LIN ; Roman L.; Shkolnik M.; Anak O.; Gogov S.; Pelov D.; Louveau A.-L.; Melichar B.Annals of Oncology6557
972015Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 doseVenkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S.Investigational New Drugs2627
982015Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategyBIN-CHI LIAO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG Therapeutic Advances in Medical Oncology1616
992015Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinomaJHE-CYUAN GUO ; Ta-Chen Huang ; CHIA-CHI LIN ; MIN-SHU HSIEH ; Chang C.-H.; PEI-MING HUANG ; JANG-MING LEE ; Feng-Ming Hsu ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU Journal of Thoracic Oncology1516
1002015Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinomaCHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu Radiotherapy and Oncology98
1012015Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisBIN-CHI LIAO ; JIH-HSIANG LEE ; CHIA-CHI LIN ; YA-FANG CHEN ; Chang C.-H.; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG Journal of Thoracic Oncology129113
1022015Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancerTa-Chen Huang ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-KANG TU Japanese Journal of Clinical Oncology2926
1032015Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Current Opinion in Oncology117109
1042014A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsGhamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S.Investigational New Drugs2115
1052014Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancerGalsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Urologic Oncology: Seminars and Original Investigations227
1062014A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesCHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG British Journal of Cancer6061
1072014An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerStadler W.M.; Vaughn D.J.; Sonpavde G.; Vogelzang N.J.; Tagawa S.T.; Petrylak D.P.; Rosen P.; CHIA-CHI LIN ; Mahoney J.; Modi S.; Lee P.; Ernstoff M.S.; Su W.-C.; Spira A.; Pilz K.; Vinisko R.; Schloss C.; Fritsch H.; Zhao C.; Carducci M.A.Cancer7572
1082014First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trialCHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K.European Journal of Cancer4140
1092014Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG Journal of Thoracic Oncology4435
1102014Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancerEscudier B.; Gr?nwald V.; Ravaud A.; Ou Y.-C.; Castellano D.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Beall S.; Pirotta N.; Squires M.; Shi M.; Angevin E.Clinical Cancer Research4844
1112014Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapyGalsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Pond G.; Godbold J.; Oh W.K.; Bamias A.Urologic Oncology: Seminars and Original Investigations114
1122013First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developmentsBIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Drugs1516
1132013Reply to S. ValeCHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU Journal of Clinical Oncology00
1142013Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesisCheng Y.-P.; HSIEN-YI CHIU ; Hsiao T.-L.; Hsiao C.-H.; CHIA-CHI LIN ; YI-HUA LIAO Journal of the American Academy of Dermatology1411
1152013Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapyGalsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Cancer99
1162013EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancerHSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Future Oncology76
1172013Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trialSmith D.C.; Smith M.R.; Sweeney C.; Elfiky A.A.; Logothetis C.; Corn P.G.; Vogelzang N.J.; Small E.J.; Harzstark A.L.; Gordon M.S.; Vaishampayan U.N.; Haas N.B.; Spira A.I.; Lara Jr. P.N.; CHIA-CHI LIN ; Srinivas S.; Sella A.; Sch?ffski P.; Scheffold C.; Weitzman A.L.; Hussain M.Journal of Clinical Oncology371345
1182013Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapyGalsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A.Cancer7771
1192013Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinomaAngevin E.; Lopez-Martin J.A.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Castellano D.; Soria J.-C.; Sen P.; Chang J.; Shi M.; Kay A.; Escudier B.Clinical Cancer Research112105
1202013Case reportCHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU Journal of Clinical Oncology67
1212013Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapyWEI-WU CHEN ; CHIA-CHI LIN ; TA-CHEN HUANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU Anticancer Research1111
1222013The impact of gender on outcomes in patients with metastatic urothelial carcinomaHaines L.; Bamias A.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Galsky M.D.Clinical Genitourinary Cancer1916
1232012A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumorSHIH-HUNG YANG ; CHIA-CHI LIN ; ZHONG-ZHE LIN ; Tseng Y.-L.; RUEY-LONG HONG Investigational New Drugs3327
1242011Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLCMedema R.H.; CHIA-CHI LIN ; CHIH-HSIN YANG Clinical Cancer Research6058
1252011RET mutations and medullary thyroid cancerCHIA-CHI LIN Journal of the Formosan Medical Association20
1262011Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinomaFeng-Ming Hsu ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG International Journal of Radiation Oncology Biology Physics3736
1272011PR-104 plus sorafenib in patients with advanced hepatocellular carcinomaAbou-Alfa G.K.; Chan S.L.; CHIA-CHI LIN ; Chiorean E.G.; Holcombe R.F.; Mulcahy M.F.; Carter W.D.; Patel K.; Wilson W.R.; Melink T.J.; Gutheil J.C.; Tsao C.-J.Cancer Chemotherapy and Pharmacology2625
1282011Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgeryJANG-MING LEE ; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN ; Wu M.-T.; CHIH-HUNG HSU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG ; Wang Y.-H.; Chuang T.-H.; JIN-SHING CHEN ; HSAO-HSUN HSU ; PEI-MING HUANG ; SHUENN-WEN KUO ; Lee Y.-C.Annals of Surgical Oncology2119
1292011Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patientsNg C.M.; Patnaik A.; Beeram M.; CHIA-CHI LIN ; Takimoto C.H.Cancer Chemotherapy and Pharmacology2410
1302011Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutationsCHIA-CHI LIN ; CHIH-HSIN YANG Drugs1010
1312010Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG Discovery medicine1312
1322010Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsCHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T.Journal of Thoracic Oncology2622
1332009National Center of Excellence for Clinical Trials and Research at National Taiwan University HospitalCHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO Drug Information Journal32
1342009Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder CancerCHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU International Journal of Radiation Oncology Biology Physics2722
1352009Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancerCHIA-CHI LIN ; CHIH-HSIN YANG Targeted Oncology119
1362009Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesCHIA-CHI LIN ; Beeram M.; Rowinsky E.K.; Takimoto C.H.; Ng C.M.; Geyer Jr. C.E.; Denis L.J.; De Bono J.S.; Hao D.; Tolcher A.W.; Rha S.-Y.; Jolivet J.; Patnaik A.Cancer Chemotherapy and Pharmacology22
1372009Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomyFeng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG Annals of Surgical Oncology3332
1382009Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsCHIA-CHI LIN ; Calvo E.; Papadopoulos K.P.; Patnaik A.; Sarantopoulos J.; Mita A.C.; Preston G.G.; Mita M.M.; Rodon J.; Mays T.; Yeh I.-T.; O'Rourke P.; Takimoto C.H.; Dancey J.E.; Chen H.; Tolcher A.W.Cancer Chemotherapy and Pharmacology1513
1392008Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG Lung Cancer51
1402008Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinomaCHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG Urologic Oncology: Seminars and Original Investigations87
1412008Down-regulated expression of RhoA in human conventional renal cell carcinomaYEONG-SHIAU PU ; Wang C.-W.; Liu G.-Y.; Kuo Y.-Z.; CHAO YUAN HUANG ; Kang W.-Y.; CHIA-TUNG SHUN ; CHIA-CHI LIN ; Wu W.-J.; Hour T.-C.Anticancer Research55
1422008Systemic therapy for metastatic urothelial carcinomaCHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU ; Vogelzang N.J.BJU International73
1432008Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trialCHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG Lung Cancer1411
1442008Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized studyFENG-MING HSU ; CHIA-CHI LIN ; JANG-MING LEE ; YIH-LEONG CHANG ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG Journal of Surgical Oncology3129
1452007Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II studyCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU Anti-Cancer Drugs3229
1462007Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based RegimensCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU Urology2421
1472007Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancerCHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C.Annals of Oncology3836
1482007A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancerCHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG Anticancer Research22
1492007Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinomaCHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU Anti-Cancer Drugs108
1502007Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trialCHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG Investigational New Drugs103102
1512007Novel targeted therapies for advanced esophageal cancerCHIA-CHI LIN ; Papadopoulos K.P.Diseases of the Esophagus1212
1522007Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trialCHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU Urologic Oncology: Seminars and Original Investigations66
1532007Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial CarcinomaCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Vogelzang N.J.; YEONG-SHIAU PU Journal of Urology2018
1542006Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case studyCHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU Anticancer Research00
1552006Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancerHour T.-C.; YEONG-SHIAU PU ; CHIA-CHI LIN ; Huang S.-W.; Chen J.; Chiu A.W.; Chen C.-J.; CHAO-YUAN HUANG Anticancer Research108
1562006Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicityCHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU Cancer2424
1572006Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cellsYEONG-SHIAU PU ; Hsieh M.-W.; Wang C.-W.; Liu G.-Y.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Guan J.-Y.; Lin S.-R.; Hour T.-C.Biochemical Pharmacology3835
1582004Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxideHour T.-C.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Chen J.; Guan J.-Y.; Lee J.-M.; YEONG-SHIAU PU Anti-Cancer Drugs2423
1592004Changing trends of prostate cancer in AsiaYEONG-SHIAU PU ; Chiang H.-S.; CHIA-CHI LIN ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.Aging Male1030
1602002A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilCHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH Anticancer Research1212
1612001A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancerCHIA-CHI LIN ; CHIH-HUNG HSU ; Chen J.; Tsai T.-C.; ANN-LII CHENG ; YEONG-SHIAU PU Anticancer Research1413